Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share
Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, now designated ABNCoV2 under exclusive license to Bavarian Nordic, and ExpreS[2]ion’s planned exercise of the option to inlicense the AV001/ES2B-C001 breast cancer vaccine candicate from its joint venture